Main Download report Dansk Novozymes.com
Print Print
Audited by PwC

Share information

The Novozymes share in 2005
The price of the Novozymes B share ended the year at DKK 345, up DKK 67 or 24% from the beginning of the year. This positive performance came in a year when expectations for profit and free cash flow were revised upwards on two occasions, and despite Novozymes posting slightly lower sales growth in local currencies than anticipated at the beginning of the year.

The Novozymes share performed 13 percentage points worse than the Copenhagen Stock Exchange's OMXC20 blue-chip index, which climbed 37% during the year. Relative to other relevant stock indices the trend was also for the Novozymes share to gain less than the average. However, the Novozymes share outperformed the Dow Jones Sustainability.

In September 2005, for the fifth year in a row, Dow Jones Sustainability Indexes named Novozymes as the listed biotechnology company with the greatest capacity, both in Europe and worldwide, to generate long-term shareholder value by exploiting opportunities and managing risks deriving from economic, environmental and social factors.

Novozymes' market capitalisation at the end of the year was DKK 24 billion. The share was the 12th most traded on the Copenhagen Stock Exchange, placing it midway up the OMXC20 index. Share turnover was fairly stable during the year. On an average day 236,000 shares were traded, equivalent to 2.1% of the value of trading in all OMXC20 shares.

At Novozymes A/S' Annual Meeting of Shareholders on March 16, 2005 a decision was taken to write down the share capital. Following this write-down, the share capital is DKK 696 million, corresponding to 69.6 million shares.

Novozymes invested a total of DKK 1,053 million in share buy-backs in 2005, and holdings of treasury shares made up 8.2% of the total share capital at year-end.

Novozymes' B share in 2005 – relative share price performance versus relevant indices

Graf_Kursudvikling_UK.gif

Share-related key figures

2005

2004

Share price (DKK)

– high

349.5 

293.0

– low

265.5 

213.0

– year-end

345.0 

278.0

Year-end market capitalisation and turnover (DKK billion)

– A shares

3.7 

3.0

– B shares

20.3 

17.2

– total

24.0 

20.2

Turnover, all trades

15.9 

9.7

No. of shares, average (million)

diluted

67.1 

69.8

No. of shares, year-end (million)

– issued

69.6 

72.6

– outstanding

63.9 

66.6

diluted

65.6 

69.8

2005

2004

Shares not strategically owned (free float)

– all shares

74.5%

74.5%

– B shares

88.1%

87.4%

Key figures

Earnings per share, diluted (DKK) 

12.79 

10.94

Cash flow from operating activities per share, diluted (DKK)

19.77 

18.43

Dividend per share (DKK)

4.00 

3.50

Year-end dividend yield (%)

1.2 

1.3

     

Background information on the Novozymes share

Novozymes A/S' B shares are listed on the Copenhagen Stock Exchange and are traded under ticker code NZYM B and ISIN DK0010272129. They have a nominal value of DKK 10 each.

 

Share capital and voting rights 
 

Share capital (DKK)

 

Votes 

 

Votes (%)

A shares

 

107,487,200

 

1,074,872,000

 

64.6

B shares

 

588,512,800

 

588,512,800

 

35.4

Total

 

696,000,000

 

1,663,384,800

 

100.0

The A share capital is held by Novo A/S, which is wholly owned by the Novo Nordisk Foundation. In addition, Novo A/S holds 6,999,280 B shares, which overall gives Novo A/S 25.5% of the total share capital and 68.8% of the votes. This is why Novozymes is included in the consolidated accounts of the Novo Nordisk Foundation. Novo A/S is domiciled in Gladsaxe, Denmark.

Novozymes' holding of treasury shares has been included when calculating the numbers and percentages of votes held.

Breakdown of shareholders

Name

% of total
share
capital

   

% of B
share
capital

Novo A/S, Gladsaxe, Denmark 

25.5%

11.9%

Novozymes A/S, Gladsaxe, Denmark 

8.2%

9.7%

Danish ATP, Hillerød, Denmark

5.5%

6.5%

Jupiter Asset Management

5.3%

6.3%

Institutional investors, etc.

45.0%

53.2%

Private investors

10.5%

12.4%

Total

100%

100%

It is estimated that the number of private shareholders is approximately 55,000, of whom around 33,000 are registered by name.

Geographical distribution of shareholders

Country/region

% of total
share
capital

 

% of B
share
 capital

Denmark

64%

 

57%

North America

15%

 

18%

UK

15%

 

18%

Rest of Europe

4%

 

5%

Asia Pacific, etc.

2%

 

2%

Total

100%

 

100%

Further information about the Novozymes share can be found under Investor zone at www.novozymes.com.

Dividend
The Board of Directors proposes payment of a dividend of DKK 4.00 per share for 2005, compared with DKK 3.50 per share for 2004. The dividend is disbursed in DKK less the statutory 28% deduction of Danish withholding tax. Shareholders resident in some countries may be eligible for a refund of withholding tax deducted in Denmark, subject to the double-taxation agreements in force between Denmark and the countries concerned.

Dividend dates

  • Resolution adopted at the Annual Meeting of Shareholders: March 1, 2006
  • Last day of trading with right to dividend for 2005: March 1, 2006
  • First day of trading without right to dividend for 2005: March 2, 2006
  • Calculation date: March 6, 2006
  • Disbursement of dividend: March 7, 2006

Financial calendar

March 1, 2006

 

Annual Meeting of Shareholders, Ballerup Superarena, Marbækvej 6, 2750 Ballerup, Denmark

April 26, 2006

 

First quarter 2006 Group financial statement

August 8, 2006

 

First half 2006 Group financial statement

October 25, 2006

 

First three quarters 2006 Group financial statement

Shareholder magazine and annual report
The shareholder magazine The Zymes is distributed twice a year to all shareholders registered by name, in connection with the notice convening the Annual Meeting of Shareholders and after the publication of the financial statement for the first half of the year. The full annual report can be found at www.novozymes.com. A printed summary can be ordered via www.novozymes.com or by contacting Novozymes directly.

Equity analysts and investor relations guidelines
A detailed list of the equity analysts covering Novozymes can be found under Investor zone at www.novozymes.com.

The following 20 companies were covering the company at year-end: ABG Sundal Collier, ABN AMRO/Alfred Berg, Alm. Brand Børs, Carnegie, Cazenove, Chevreaux, Danske Equities, Enskilda Securities, Handelsbanken Capital Markets, HSBC, J.P. Morgan Securities, Jyske Bank, Merrill Lynch, Nordea Securities, Proactive Independent Ideas (PI Ideas), SG Securities, Spar Nord, Sydbank, UBS and Vontobel.

Novozymes' investor relations guidelines can be viewed under Investor zone at www.novozymes.com.

Dialogue and contact
Visit Investor zone at www.novozymes.com for information for both private and institutional shareholders, or contact Investor Relations:

Lene Aaboe, senior director
Tel. +45 4446 0082, mobile +45 3077 0082, fax +45 4442 1002
lefr@novozymes.com

Tobias Björklund, manager
Tel. +45 4442 8286, mobile +45 3079 8286, fax +45 4442 1002
tobb@novozymes.com

Registration number
Novozymes A/S is registered with the Danish Commerce and Companies Agency under 10 00 71 27.

© Novozymes 2006 Krogshøjvej 36 - DK-2880 Bagsværd - +45 8824 9999 - info@novozymes.com Privacy | Legal | About The Novozymes Report